Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498535 | 0.81 | LSS (0.55) | LSSSIGMAR1CYP1A2CYP2D6MEN1 | |
| SCHEMBL19993063 | 0.81 | LSS (0.55) | LSSSIGMAR1CYP1A2CYP2D6MEN1 | |
| SCHEMBL19212128 | 0.81 | LSS (0.55) | LSSSIGMAR1CYP1A2CYP2D6MEN1 | |
| SCHEMBL10264241 | 0.79 | LSS (0.59) | LSSDRD2QDPR | |
| SCHEMBL20630095 | 0.79 | LSS (0.52) | LSSSIGMAR1CYP1A2CYP2D6MEN1 | |
| SCHEMBL14081034 | 0.78 | LSS (0.51) | LSSSIGMAR1CYP1A2CYP2D6MEN1 | |
| SCHEMBL23173450 | 0.77 | LSS (0.58) | LSSSIGMAR1MEN1KMT2ADRD2 | |
| SCHEMBL21462239 | 0.77 | LSS (0.62) | LSSSIGMAR1MEN1KMT2ADRD2 | |
| SCHEMBL15177091 | 0.77 | LSS (0.58) | LSSSIGMAR1MEN1KMT2ADRD2 | |
| SCHEMBL2426347 | 0.77 | LSS (0.58) | LSSDRD2QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | LSS 3469/4885SIGMAR1 4420/4885CYP1A2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.